A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 Oral Solution in Patients With Parkinson's Disease of Moderate Severity Responding to Immediate-Release Oral Levodopa/Carbidopa and Withdrawn From Levodopa/Carbidopa

Trial Profile

A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 Oral Solution in Patients With Parkinson's Disease of Moderate Severity Responding to Immediate-Release Oral Levodopa/Carbidopa and Withdrawn From Levodopa/Carbidopa

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs SAGE 217 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Proof of concept
  • Sponsors Sage Therapeutics
  • Most Recent Events

    • 02 Nov 2017 Top-line results for Part B published in a Sage Therapeutics Media Release.
    • 20 Oct 2017 Status changed from recruiting to completed.
    • 04 Aug 2017 According to a Sage Therapeutics Media Release, Part B study has been initiated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top